UTMB Health
Welcome,         Profile    Billing    Logout  
 1 Trial 
14 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Klimberg, Suzanne
NCT04974567: Tear Based Sample Collection Breast Cancer Detection

Active, not recruiting
N/A
50
US
Schirmer Strip
Namida Lab, The University of Texas Medical Branch, Galveston
Breast Cancer, Tear, Breast Cancer Female
08/24
09/25
Siri, Dareen
NCT06372496: Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma

Recruiting
4
1136
Canada, Japan, US, RoW
Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate, Inhaled corticosteroids/long-acting beta-2 agonists
GlaxoSmithKline
Asthma
03/26
03/26
NCT05757102: A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

Recruiting
3
292
US, RoW
FF/UMEC/VI, ELLIPTA, FF/VI
GlaxoSmithKline
Asthma
01/27
01/27
NCT05243680 / 2020-004334-38: An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

Active, not recruiting
3
641
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
05/25
05/25
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Hourglass Feb 2024 - Jun 2024 : Acceptance of regulatory submission in China for CRSwNP
Active, not recruiting
3
1667
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
10/25
10/25
TAK-881-3002, NCT06076642: A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

Recruiting
3
39
US
TAK-881, Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (rHuPH20)., SC Investigational Needle Sets
Takeda, Takeda Development Center Americas, Inc., Baxalta Innovations GmbH, now part of Takeda
Primary Immunodeficiency Diseases (PID)
01/29
01/29
NCT05755035: A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

Recruiting
2/3
75
Europe, US, RoW
TAK-881, Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (rHuPH20)., HYQVIA, Immune Globulin Infusion (Human), 10% Solution with rHuPH20.
Takeda, Takeda Development Center Americas, Inc.
Primary Immunodeficiency Diseases (PID)
02/26
09/26
NCT05667662 / 2022-002289-33: Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA

Terminated
2
8
Europe, US, RoW
Itraconazole Powder, PUR1900, Placebo
Pulmatrix Inc., Pulmatrix, Inc.
ABPA
02/24
02/24
NCT06436183: A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

Recruiting
2
60
Canada, US
Camoteskimab, APL-9109, AVTX-007, CERC-007, AEVI-007, MEDI2338, Placebo
Apollo Therapeutics Ltd
Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
02/25
06/25
NCT05432388 / 2021-006950-30: Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts

Recruiting
2
72
Europe, US
remibrutinib, (LOU064), placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Allergy, Peanut
03/25
03/25
NCT05440643: Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy

Recruiting
1/2
192
Canada, US
Peanut SLIT-tablet, Placebo
ALK-Abelló A/S, Parexel
Peanut Allergy
01/26
02/26
Tripple, Julia
NCT05667662 / 2022-002289-33: Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA

Terminated
2
8
Europe, US, RoW
Itraconazole Powder, PUR1900, Placebo
Pulmatrix Inc., Pulmatrix, Inc.
ABPA
02/24
02/24
Sweeny, Lisa
NCT05667662 / 2022-002289-33: Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA

Terminated
2
8
Europe, US, RoW
Itraconazole Powder, PUR1900, Placebo
Pulmatrix Inc., Pulmatrix, Inc.
ABPA
02/24
02/24
Nixon, Alaine
NCT05667662 / 2022-002289-33: Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA

Terminated
2
8
Europe, US, RoW
Itraconazole Powder, PUR1900, Placebo
Pulmatrix Inc., Pulmatrix, Inc.
ABPA
02/24
02/24

Download Options